410 Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced can...
410 Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
BackgroundCancer immunotherapies have shown promising clinical outcomes; however, the majority of patients are non-responders or will develop resistance during the course of treatment. One of the current challenges is to increase the response rate to immune checkpoint inhibitors (ICIs). Combining immunotherapy with radiation therapy (RT) is emergin...
Alternative Titles
Full title
410 Phase I study of intratumoral NBTXR3 in combination with anti-PD-1 in patients with advanced cancers
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_406838b961aa46c8b39d01d5f4d91981
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_406838b961aa46c8b39d01d5f4d91981
Other Identifiers
E-ISSN
2051-1426
DOI
10.1136/jitc-2020-SITC2020.0410
